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Abstract  26 
Chemokine (C-X-C motif) ligand (CXCL)10 is involved in the pathogenesis of 27 
psoriasis. It has been demonstrated that chemokine (C-X-C motif) receptor (CXCR)3 28 
and CXCL10 were detected in keratinocytes and the dermal infiltrate obtained from 29 
active psoriatic plaques and that successful treatment of active plaques decreased the 30 
expression of CXCL10. Elevated CXCL10 serum levels have been shown in patients 31 
with psoriasis, with a type 1 T helper cells immune predominance at the beginning of 32 
the disease, while a decline of this chemokine has been evidenced later, in long lasting 33 
psoriasis. Circulating CXCL10 is significantly higher in patients with psoriasis in the 34 
presence of autoimmune thyroiditis. It has been hypothesized that CXCL10 could be a 35 
good marker to monitor the activity or progression of psoriasis. Efforts have been 36 
made to modulate or inhibit the CXCR3/CXCL10 axis in psoriasis to modify the 37 
course of the disease. 38 
 39 
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1. Introduction 42 
Psoriasis [also known as psoriasis vulgaris (PsO)] [1], affects 2–4% of the general 43 
population [2]; it is considered a chronic relapsing/remitting immune-mediated skin 44 
disease [1], and presents itchy red, scaly patches, papules, and plaques, with different 45 
severity, from minor localized patches to complete body coverage.  46 
Five main types of PsO exist: plaque, guttate, inverse, pustular, and erythrodermic [3]. 47 
Plaques are commonly evident on the skin of elbows and knees, but also on scalp, 48 
palms of hands and soles of feet. Fingernails and toenails are commonly affected 49 
(psoriatic nail dystrophy) and can be present as an isolated sign. Psoriatic arthritis 50 
(PsA) is an inflammatory arthritis linked to PsO that affects up to 30% of the patients 51 
[1].  52 
The causes of PsO are not completely known. PsO has been associated with an 53 
elevated risk of other immune-mediated disorders like Crohn's disease, ulcerative 54 
colitis and autoimmune thyroiditis [4]. It is a genetic disease, activated by 55 
environmental factors [1]. 56 
The epidermal layer of the skin typically grows rapidly in PsO [5]. The sequence of 57 
pathological events occurring in PsO determines an abnormal production and an 58 
overabundance of skin cells [6], that are replaced every 3–5 days in PsO instead of the 59 
common 28–30 days [7], probably owing to the premature maturation of 60 
keratinocytes, that is induced by an inflammatory cascade in the dermis [8]. These 61 
immune cells from dermis go to epidermis and release inflammatory molecules 62 
[tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and IL-22] [9]. These 63 
released inflammatory signals seem to stimulate the proliferation of keratinocytes [9].  64 
Markers of susceptibility for the development of PsO are considered gene mutations 65 
of proteins that are associated with the capability of skin to serve as a barrier [10, 11].  66 
In PsO, DNA is able to stimulate the receptors on some dendritic cells, to produce 67 
interferon (IFN)-α [12].  68 
Dendritic cells connect adaptive and innate immune system, are highly present in 69 
psoriatic lesions [5], inducing T cells and type 1 helper T cells (Th)1 to proliferate. 70 
The number of dendritic cells can be reduced by targeted immunotherapy and 71 
psoralen and ultraviolet A (PUVA) therapy, inducing a Th2 cytokine pattern instead 72 
of a Th1/Th17 cytokine profile [9]. In PsO, T cells from dermis go to epidermis and 73 
release IL-17 and IFN-γ [13].  74 
Until now, different treatments can help to control the symptoms [14, 15]; for 75 
example, a new generation of targeted immune therapies is still under investigation to 76 
advance treatment options for PsO, and are now needed for approval to targeted 77 
immunotherapies for PsO [16, 17]. 78 
In PsO, cytokines (as TNF-α, IL-1β, IL-6, and IL-22) [9] induce inflammatory signals 79 
and the secretion of chemokines [9]. 80 
Here, we review the role of the prototype Th1 chemokine chemokine (C-X-C motif) 81 
ligand (CXCL)10 in PsO. 82 
 83 
2. REVIEW 84 
2.1 CXCR3 chemokines 85 
Chemokines are small molecules that form a subfamily of the cell signalling 86 
cytokines. They are divided into four groups (on the basis of the existing space 87 
between the first two cysteine residues in the N-terminal region). In chemokines of 88 
the C-X-C subgroup, the two N-terminal cysteines are separated by a single and 89 
variable amino acid; CXC chemokines are further sub-divided into two subgroups: 1) 90 
ERL positive (ERL+): containing Glu-Leu-Arg sequence (ERL motif); 2) ERL 91 
negative (ERL-): without ERL motif [18, 19]. CXCL10/IFN-γ-induced protein 10 (IP-92 
10), CXCL9/monokine induced by IFN-γ (MIG) and CXCL11/Interferon Inducible T 93 
cell α (ITAC) belong to this last subgroup. These chemokines act by binding to 94 
chemokine CXC receptor 3 (CXCR3) [19], a G protein coupled receptor with seven 95 
transmembrane domains, existing in two forms: a) CXCR3-A able to bind CXCL9, 96 
CXCL10 and CXCL11; b) CXCR3-B (a splice variant) also binds (C-X-C motif) 97 
ligand 4 (CXCL4) [20]. CXCR3 and its ligands (CXCL10 is the main) have an 98 
important role in the chemotaxis of inflammatory cells, are expressed on activated T 99 
lymphocytes, above all Th1, and natural killer (NK) cells [21], but also on surface of 100 
B lymphocytes (and other cells), and are important in the development of a Th1 101 
orientated immune response.  102 
Th1 activation induces IFN-γ and TNF-α production, which stimulates secretion of 103 
CXCL10 (encoded by CXCL10 gene) [22], by the lymphocytes themselves, but also 104 
by other cells, such as neutrophils, monocytes, endothelial cells, fibroblasts, 105 
thyrocytes, keratinocytes, etc; this process leads to an amplification feedback loop 106 
which initiates and perpetuates the immune cascade (Figure 1) [19, 23, 24]. For these 107 
reasons, high levels of CXCL10 in peripheral liquids are considered a marker of a Th1 108 
orientated immune response. 109 
In animal and human allograft rejection, CXCR3 ligand expression is upregulated and 110 
there is a prevalent expression of CXCR3 on infiltrating T cells; this let hypothesize 111 
the importance of CXCR3-dependent T cell recruitment in transplant rejection [25-112 
27].  113 
CXCL10 is an important chemoattractant for neutrophils, and prominent infiltration 114 
and microabscess formation by neutrophils is a distinctive hallmark feature of PsO. 115 
Many studies have demonstrated a critical pathogenic role of neutrophils in PsO, 116 
overall in the initial phases, suggesting that blocking neutrophil function may have 117 
therapeutic benefit in this disease [28-30]. 118 
Macrophages are the source of another potential psoriasis trigger. Studies show folic 119 
acid receptors being over expressed in activated macrophages in PsO [31, 32]. 120 
However, folic acid's actions on inflammation are unusual. The endothelial-dependent 121 
response called flow-mediated vasodilation  is principally regulated by release of 122 
nitric oxide (NO) from the endothelium. NO is synthesized from the amino acid L-123 
arginine by endothelial nitric oxide synthase (eNOS). Five mg/day - but not 400 124 
µg/day folic acid improves blood vessel cell function measured by flow-mediated 125 
vasodilation in coronary artery disease patients. The inactive monomer of eNOS 126 
results in a reduction of net NO synthesis and increases superoxide generation [33].  127 
Dimeric eNOS is anti-inflammatory, and monomeric is pro-inflammatory, showing 128 
the dual nature of this mechanism. This suggests that high-dose folic acid can also 129 
have important anti-inflammatory potentials [34-36]. Etanercept-cleared psoriasis skin 130 
has 87% less inducible nitric oxide synthase (iNOS) from tissue using a reverse 131 
transcriptase PCR assay [37]. 132 
Attempts to treat PsO using this hypothesis to date have been mixed [38]. 133 
 134 
2.2 CXCL10 in autoimmunity 135 
 136 
Stimulated by cytokines, various cell types (T lymphocytes, monocytes, fibroblasts, 137 
thyrocytes, preadipocytes, etc.) secrete CXCL10. Accordingly, a marker of host 138 
immune response, in particular Th1 orientated T-cells, is the presence of elevated 139 
levels of CXCL10 in peripheral liquids.  140 
The increased IFN-γ and TNF-α production, related to the recruitment of Th1 141 
lymphocytes, stimulates the CXCL10 secretion from the abovereported cells, creating 142 
an amplification feedback loop [19]. 143 
Serum CXCL10 levels increase with advancing age [39], and serum and/or tissue 144 
expression levels are augmented in organ specific autoimmune diseases, as type 1 145 
diabetes [40-43], Graves’ disease or Graves’ ophthalmopathy [44-46], autoimmune 146 
thyroiditis [47, 48], or systemic rheumatological disorders, like rheumatoid arthritis 147 
[49], systemic lupus erythematosus [50], systemic sclerosis [51-53], PsO or PsA [4, 148 
54, 55], sarcoidosis [56], HCV-related cryoglobulinemia [57-60], other HCV immune 149 
mediated disorders [61-65], and also in cancers [66-71].  150 
 151 
2.3 CXCL10 in psoriasis 152 
 153 
Inflammation and an elevated epidermal turnover are pathological characteristics of 154 
psoriatic plaques.  155 
Pathological event in PsO begins with inflammatory cascade in dermis [72]. 156 
CXCL10 was evidenced in dermal infiltrate and keratinocytes obtained from active 157 
psoriatic plaques [73]; an effective therapy decreased its expression in plaques.  158 
As it will be shown later fumaric acid esters and apremilast act in part reducing 159 
CXCL10. 160 
Northern blot analysis confirmed these data with a CXCL10 cDNA probe. Activated 161 
T cells and HLA-DR keratinocytes have been previously revealed in active psoriatic 162 
plaques. As CXCL10 is detected in delayed cellular immune responses, the 163 
significance of ongoing cellular immune responses in the pathogenesis of PsO has 164 
been investigated [73]. 165 
Another study found a strongly elevated constitutive transcriptional activity of the 166 
CXCL10 gene in unstimulated keratinocytes, not stimulated by IFN-γ, TNF-α, or their 167 
combination [74]. 168 
Immunohistochemical techniques evidenced that the cellular infiltrate in acute 169 
psoriatic plaques is constituted by 5-8% CD3(-)CD56(+) NK cells, particularly 170 
localized in the mid and papillary dermis. NK lymphocyte migration towards 171 
CXCL10 is implicated in the pathogenesis of psoriasis [75]. 172 
IL-27, a member of IL-12 family, is a recently discovered cytokine, involved in the 173 
priming of Th1 cells. The pathophysiological significance of IL-27 has been reported 174 
and discussed in Th1/Th17-mediated inflammatory diseases in the paper by Shibata et 175 
al. [76]. Psoriatic patients had elevated serum IL-27 levels with respect to those of 176 
healthy controls, that significantly correlated with disease severity and with the levels 177 
of IFN-γ. These data suggest that the increased IL-27 levels may contribute to the 178 
enhanced Th1 activity in psoriatic patients. The infiltration of IL-27-secreting cells in 179 
the papillary dermis of skin lesions in PsO has been shown by immunohistochemical 180 
analysis, but not in skin lesions in the presence of atopic dermatitis (AD) or normal 181 
skin. These data indicate that IL-27 may specifically act in psoriatic lesions. IL-27 182 
alone induced strongly the in vitro secretion of CXCL9, CXCL10, and CXCL11 in 183 
normal human keratinocytes, while it inhibited the TNF-α-induced secretion of IL-1α 184 
and CCL20. These chemokines selectively attract activated Th1 cells through 185 
CXCR3. The expression of these chemokines is upregulated in the keratinocytes of 186 
psoriatic skin lesions. These data lead to hypothesize that IL-27 might promote 187 
through CXCR3 chemokines (mainly CXCL10) the Th1-type inflammation in the 188 
absence of other inflammatory mediators in psoriatic patients and contribute to the 189 
onset of the disease [76]. 190 
Intra-epidermal cutaneous lymphocyte antigen (CLA)+ and integrin αEβ7+ T 191 
lymphocytes selectively expressed CXCR3, in PsO, suggesting an involvement of 192 
CXCR3 (and through it CXCL10) and CC chemokine receptor (CCR)4 in T 193 
lymphocyte trafficking to the psoriatic dermis and of CXCR3 in the following T cell 194 
homing to the overlying epidermis [77]. 195 
In PsO, keratinocytes have an intrinsically huge and different chemokine production 196 
profile, favoring the recruitment of distinct leukocyte subsets into the skin, and 197 
showed significantly more elevated levels of constitutive and induced IL-8 and a 198 
stronger induction of CXCL10, than in AD [78].  199 
Immunohistochemical staining showed cutaneous CXCL10 was strongly expressed in 200 
lesional keratinocytes in PsO and focally in AD [79]. 201 
Keratinocytes functionally respond to IL-18 with the upregulation of major 202 
histocompatibility complex II and secretion of CXCL10, suggesting a key role of IL-203 
18 in inflammatory skin diseases in the epidermis [80]. 204 
Prolactin and IL-18 enhance CXCL9, CXCL10, and CXCL11 in human keratinocytes, 205 
and promote type 1 T cell infiltration into psoriatic lesions through these chemokines 206 
[81, 82]. 207 
Circulating CCL2 and CXCL10 were tested in 68 PsA patients, and in gender- and 208 
age-matched (1:1) control subjects selected from the general population [53]. 209 
Circulating CXCL10 mean is significantly more elevated in PsA patients than in 210 
control subjects. Considering a high CXCL10 level as a value at least 2 SD above the 211 
mean value of the control group (>198 pg/ml), 49% of patients with PsA and 5% of 212 
controls showed high CXCL10. Considering CXCL10 circulating levels and disease 213 
duration, a significant inverse correlation was evidenced. Also mean circulating CCL2 214 
levels were significantly higher in patients with PsA than in controls. In conclusion, 215 
elevated CXCL10 and CCL2 levels are shown in PsA patients, with a Th1 immune 216 
predominance at the beginning of the disease, and a decline of CXCL10 in long 217 
lasting disease, with a significant increase of the CCL2/CXCL10 ratio. This suggests 218 
a switch from Th1 to Th2 immune response in long duration PsA [53]. 219 
However, discordant results have been recently reported [83].  220 
In a previous paper [54] we evaluated circulating CXCL10 (α) and CCL2 (β) in a 221 
large series of patients with PsA, with/without autoimmune thyroid (AT) disorders, to 222 
connect the obtained levels to the clinical phenotype. 223 
Considering an elevated CXCL10 level as a value of at least 2 SD above the mean 224 
value of the control group, 5% of control 1, 19% of control 2, 42% of PsA and 63% of 225 
PsA+AT, showed elevated levels of CXCL10. In conclusion, higher circulating 226 
CXCL10 and CCL2 have been demonstrated in PsA patients than in control subjects. 227 
Circulating CXCL10 in PsA is significantly higher in the presence of AT [54].  228 
The involvement of IL-27 in the pathogenesis of PsO was investigated also in induced 229 
psoriasis-like inflammation on mouse back skin with topical application of imiquimod 230 
(IMQ), and subcutaneous injections of IL-27 or phosphate-buffered saline (PBS) [84]. 231 
Elevated levels of IL-27 mRNA and the presence of infiltration of IL-27-producing 232 
cells in the papillary dermis has been revealed in IMQ-treated skin. Injecting IL-27 in 233 
the IMQ-treated skin the disease worsened with respect to the injection of PBS. The 234 
mRNA levels of IFN-γ, CXCL9, CXCL10, CXCL11, and TNF-α increased with the 235 
injection of IL-27, but not those of IL-17F, IL-17A, IL-22, and CCL20. At last, IL-27 236 
antagonism reduced the upregulation of IFN-γ, CXCL9, CXCL10, CXCL11, and 237 
TNF-α mRNA levels, and led the IMQ-treated skin to improve clinically and 238 
histologically. These data show IL-27 may act in a proinflammatory way, 239 
exacerbating the psoriasis-like skin inflammation IMQ-induced [84]. 240 
It was also demonstrated that a psoriasis-associated risk haplotype at the IL-12B locus 241 
causes an elevated expression of IL-12B by monocytes and correlated with increased 242 
circulating IL-12, IFN-γ and the IFN-γ-induced chemokine, CXCL10 [85].  243 
 244 
2.4 CXCR3 and CXCL10 as targets of therapies in PsO 245 
 246 
The PsO systemic treatment with fumaric acid esters has demonstrated its efficacy, 247 
even if their cellular and molecular mechanism of action is still unknown. The 248 
efficacy of dimethylfumarate on the release of CXCL1, CXCL8, CXCL9, CXCL10 249 
and CXCL11 in human keratinocytes and peripheral blood mononuclear cells has 250 
been evaluated. It has been shown that dimethylfumarate dose-dependently inhibited 251 
CXCL1, CXCL8, CXCL9, CXCL10 and CXCL11 transcription. This could partly 252 
clarify the positive effects of the therapy with fumaric acid esters in PsO, as 253 
dimethylfumarate is able to inhibit the production of chemokines that may be 254 
critically involved in the development and perpetuation of psoriatic lesions [86]. 255 
In psoriatic skin, NO is highly produced by epidermal keratinocytes in response to 256 
IFN-γ and TNF-α [87]. A research investigated whether the NO donors, S-257 
nitrosoglutathione (GS-NO) and (±)-(E)-methyl-2-((E)-hydroxyimino)-5-nitro-6-258 
methoxy-3-hexenamide (NOR-1), could modulate the chemokine secretion by human 259 
keratinocytes activated with IFN-γ and TNF-α. GS-NO-treated psoriatic skin showed 260 
reduction of CXCL10, CCL2, and RANTES, but not IL-8 expression by 261 
keratinocytes. In keratinocytes, these data indicate that NO donors are able to 262 
negatively regulate the chemokine production [87]. 263 
The result of TNF/lymphotoxin blockade with etanercept (soluble TNFR) was 264 
investigated in 10 patients with PsO treated for 6 months [88], in particular the 265 
histological response, inflammatory gene expression, and cellular infiltration in 266 
psoriasis plaques. IL-1 and IL-8, CXCL10, and CCL20 mRNA expression reduced 267 
rapidly and completely, that may be justified by a reduced infiltration of T cells, 268 
neutrophils, and dendritic cells. This causes an overturning of the epidermal 269 
hyperplasia and cutaneous inflammation typical of psoriatic plaques [88]. 270 
Apremilast is an orally administered phosphodiesterase-4 inhibitor, used in clinical 271 
studies of PsO. Apremilast inhibited in vitro the secretion of CXCL9, CXCL10, IFN-272 
γ, TNF-α, and IL-2, IL-12 and IL-23 from human primary peripheral blood 273 
mononuclear cells, suggesting a new strategy for the treatment of PsO [89, 90]. 274 
Apremilast has been approved by both the United States FDA and European 275 
Medicines Agency for treatment of PsA [89, 91].  276 
Recently, the two terpenes costunolide (CS) and dehydrocostuslactone (DCE), 277 
naturally present in many plants, have been demonstrated to be able to have anti-278 
inflammatory effects on various human cell types. The role of CS and DCE in the 279 
regulation of proliferative and inflammatory responses to cytokines in human 280 
keratinocytes has been evaluated. CS and DCE reduced glutathione (GSH) 281 
intracellularly in human keratinocytes, and inhibited STAT3 and STAT1 282 
phosphorylation and activation triggered by IL-22 or IFN-γ, respectively. As a 283 
consequence, CS and DCE reduced the IL-22- and IFN-γ-induced expression of 284 
inflammatory and regulatory genes in keratinocytes, including CCL2 and CXCL10. It 285 
was hypothesized that using CS and DCE in PsO therapy the pro-inflammatory 286 
actions of IFN-γ and IL-22 on keratinocytes may be reduced [92]. 287 
 288 
3. Conclusions 289 
CXCL10 is involved in the pathogenesis of PsO. It was shown that CXCR3 and 290 
CXCL10 were evidenced in keratinocytes and the dermal infiltrate from active 291 
psoriatic plaques; an effective therapy of active plaques reduced CXCL10 expression 292 
in plaques. In PsO, elevated serum levels of CXCL10 have been demonstrated, with a 293 
Th1 immune predominance at the beginning of the disease, and a decline of CXCL10 294 
levels in long lasting PsO. Circulating CXCL10 (α chemokine) levels in patients with 295 
PsO are significantly higher in the presence of AT. It has been hypothesized that 296 
CXCL10 could be a good marker to monitor the activity or progression of PsO.  297 
Since CXCL10 is an important marker of inflammation in PsO, it is used to evaluate 298 
genetic susceptibility [85], or the anti-inflammatory activity of new therapies [89, 93]. 299 
Furthermore, selective and potent CXCR3 or CXCL10 antagonists have been 300 
evaluated in autoimmune diseases, and it has been suggested a possible use also in 301 
PsO [16, 17]. 302 
303 
Figure Legend 303 
Figure 1. Activated Th1 lymphocytes produce IFN-γ and TNF-α, which stimulate 304 
secretion of CXCL10, by the lymphocytes themselves, but also by other cells (dermal 305 
fibroblasts, keratinocytes, endothelial cells, etc); this process leads to an amplification 306 
feedback loop which initiates and perpetuates the immune cascade. 307 
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